Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting PKLR and lipogenic enzymes through JNK inhibition to develop a therapeutic strategy for MASLD and MASH.

Frontiers in pharmacology·2026
Same author

Pycnogenol attenuates thioacetamide-induced neurobehavioral impairment and hepatotoxicity via multi-target molecular modulation.

BMC pharmacology & toxicology·2026
Same author

Investigation of anticancer effects of Boswellia serrata extract in combination with SN-38 on U373 GBM cells.

Molecular biology reports·2026
Same author

Alternative therapy against CTX-M broad spectrum β-lactamase resistance gene in Klebsiella pneumoniae infection: bee venom and bee venom-derived nanovesicle fraction.

Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]·2026
Same author

Combined <i>in vitro</i> effects of temozolomide and erucic acid on U87 MG cell viability, oxidative stress, and expression of genes involved in apoptotic signalling.

Arhiv za higijenu rada i toksikologiju·2026
Same author

Naked-eye fluorescence sensing of aluminum using a bis(rhodamine)-phenyl hybrid for environmental monitoring and in vitro/in vivo bioimaging.

Mikrochimica acta·2026

Related Experiment Video

Updated: Apr 30, 2026

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-&#946; and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

29.8K

Multi-Target Neuroprotective Compound Exhibits EAAT2-Modulating and Alzheimer's Pathology-Attenuating Effects in In

Ahmet Hacımüftüoğlu1, Nurullah Saraçoğlu2,3, Sana Saffour4

  • 1Department of Medical Pharmacology, Faculty of Medicine, Atatürk University, 25240 Erzurum, Turkey.

ACS Chemical Neuroscience
|April 29, 2026
PubMed
Summary

A novel compound, HCM-01, shows promise for Alzheimer's disease (AD) by protecting neurons from glutamate excitotoxicity and improving cognitive function in animal models. It also modulates glutamate homeostasis and redox balance, suggesting a multitarget therapeutic approach for early AD.

Keywords:
Tau pathologyglutamate excitotoxicityneurodegenerationoxidative stressβ-Amyloid pathology

More Related Videos

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
06:41

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Published on: January 10, 2025

1.3K
Visualizing Axonal Growth Cone Collapse and Early Amyloid &#946; Effects in Cultured Mouse Neurons
06:23

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Published on: October 30, 2018

7.1K

Related Experiment Videos

Last Updated: Apr 30, 2026

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-&#946; and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

29.8K
Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
06:41

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Published on: January 10, 2025

1.3K
Visualizing Axonal Growth Cone Collapse and Early Amyloid &#946; Effects in Cultured Mouse Neurons
06:23

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Published on: October 30, 2018

7.1K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder with limited treatment options.
  • Current AD therapies offer minimal efficacy, highlighting the need for novel multitarget strategies.
  • Glutamate excitotoxicity, impaired glutamate homeostasis, and oxidative stress are key pathological mechanisms in AD.

Purpose of the Study:

  • To develop and evaluate a novel multitarget compound, HCM-01, for Alzheimer's disease.
  • To investigate HCM-01's neuroprotective effects against glutamate excitotoxicity in vitro.
  • To assess HCM-01's impact on astrocytic glutamate handling, redox balance, and in vivo cognitive function in an AD model.

Main Methods:

  • In vitro assays: MTT viability in primary neurons and astrocytes exposed to glutamate.
  • Western blot analysis for EAAT2 expression in astrocytes.
  • Redox analysis for total antioxidant capacity (TAC) and total oxidant status (TOS).
  • In vivo studies: STZ-induced AD rat model assessing cognitive function (PA, MWM, locomotor activity).
  • Histopathological and immunohistochemical analyses of hippocampal tissues.
  • In silico molecular docking, molecular dynamics simulations, and free energy calculations.

Main Results:

  • HCM-01 significantly improved neuronal viability against glutamate excitotoxicity, outperforming donepezil and memantine.
  • HCM-01 increased EAAT2 expression in astrocytes, suggesting modulation of glutamate homeostasis.
  • HCM-01 improved the oxidative/antioxidative balance by increasing TAC and reducing TOS.
  • In vivo, HCM-01 administration significantly enhanced cognitive and memory functions in an STZ-induced AD rat model.
  • Histopathology revealed reduced neuronal damage, attenuated tau pathology, anti-amyloidogenic effects, and restored cholinergic function.
  • In silico studies indicated potential interaction of HCM-01 with the allosteric site of EAAT2.

Conclusions:

  • HCM-01 demonstrates significant neuroprotective effects against excitotoxicity and improves cognitive deficits in an AD model.
  • The compound modulates glutamatergic homeostasis and redox balance, supporting its multitarget mechanism of action.
  • HCM-01 represents a promising preclinical candidate for targeting early-stage Alzheimer's disease mechanisms.